Compare NEXT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | TSHA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | NEXT | TSHA |
|---|---|---|
| Price | $5.02 | $5.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $9.00 | ★ $10.56 |
| AVG Volume (30 Days) | ★ 3.6M | 3.4M |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.99 | $1.05 |
| 52 Week High | $12.12 | $6.02 |
| Indicator | NEXT | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 50.81 |
| Support Level | $5.23 | $4.80 |
| Resistance Level | $5.47 | $6.02 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 29.01 | 43.03 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.